决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Microphysiological Solid Tumor Models in Hydrogel Beads for CAR T Cell Immunotherapy Evaluation.
微转移灶在手术切除和体内成像检测方面均具有挑战性。
微转移灶在外科切除和体内成像检测方面均具有挑战性。免疫治疗被高度期待能彻底改变其治疗,但其对实体瘤的整体疗效仍然有限。在此,开发了一种 3D 微转移模型,以模拟关键微环境线索,从而能够在体外评估嵌合抗原受体 (CAR) T 细胞免疫治疗。以优先转移至例如肝脏或骨髓的前列腺癌作为模型。弹性模量与软器官相匹配的水凝胶珠被用于支持球状体的长期培养、免疫染色和监测。作为生化线索,研究成纤维细胞活化蛋白 (FAP)——肿瘤微环境中的一个新兴靶点——对前列腺癌球状体以及 CAR T 细胞治疗疗效的影响。该多球状体模型由表达前列腺干细胞抗原 (PSCA) 的前列腺癌细胞和产生 FAP 的纤维肉瘤细胞以不同比例组成。该模型的形态学特征与临床组织病理学和转移性小鼠模型样本进行比较。最后,CAR T 细胞试验证明成功的趋化吸引和穿过水凝胶基质的浸润,针对 FAP 和 PSCA 抗原的双靶向策略显示出协同疗效。这项研究为工程化 3D 肿瘤模型和对靶向小转移瘤或残留瘤的治疗进行建模提供了宝贵见解,表明共靶向可能是解除肿瘤微环境抑制的更有效策略。
Micrometastases are challenging to resect surgically and to detect with in vivo imaging. Immunotherapy is highly anticipated to revolutionize their treatment, but its overall efficacy still remains limited for solid tumors. Here, a 3D micrometastases model is developed to mimic key microenvironmental cues, enabling in vitro evaluation of chimeric antigen receptor (CAR) T cell immunotherapy. Prostate cancer that preferentially metastasizes to, e.g., liver or bone marrow, is utilized as a model. Hydrogel beads with an elastic modulus matching those of soft organs are used to support long-term culturing, immunostaining, and monitoring of the spheroids. As a biochemical cue, the impact of fibroblast activation protein (FAP), an emerging target in the tumor microenvironment, is investigated on prostate cancer spheroids and on the efficacy of CAR T cell therapy. The multi-spheroid model consists of prostate stem cell antigen (PSCA)-expressing prostate cancer cells and FAP-producing fibrosarcoma cells in varying ratios. The morphological features of the model are compared to clinical histopathology and metastatic murine model samples. Finally, CAR T cell trials demonstrate successful chemoattraction and infiltration through the hydrogel matrix, with a dual-targeting approach against FAP and PSCA antigens showing synergistic efficacy. This research provides invaluable insights for engineering 3D tumor models and modeling therapies targeting small metastatic or residual tumors, suggesting that co-targeting may be a more effective strategy to unlock the tumor microenvironment's suppression.
MEMBER ACCOUNT
登录成功会直接打开下一页。